Keep Blood Cancer Away®

Find your blood cancer

Who is at risk

For most blood cancers, no cause is ever found. They are not contagious, not inherited in the usual sense, and not caused by stress or diet. The recognised associations across the group are:

• Age — most blood cancers become more common with age. The exceptions matter: acute lymphoblastic leukemia peaks in early childhood, and Hodgkin lymphoma has a young-adult peak.
• A suppressed immune system — HIV, transplant anti-rejection drugs, long-term immunosuppression.
• Previous chemotherapy or radiation for another cancer, which can cause a therapy-related leukemia or MDS years later.
• Certain infections — Epstein-Barr virus, H. pylori, hepatitis C, HTLV-1.
• Benzene and some industrial exposures; smoking is linked to AML.
• Preceding blood conditions — MGUS before myeloma, MDS before AML.
• Race — myeloma is about twice as common in Black Americans, and diagnosed younger.

How they’re found and diagnosed

There is no population screening for blood cancers. They are found because a symptom prompted a test, or because a routine blood count came back abnormal.

The symptoms are the symptoms of blood not working: fatigue and breathlessness (anaemia), repeated or stubborn infections (low white cells), easy bruising, tiny red skin spots or bleeding gums (low platelets). Add painless swollen lymph nodes, drenching night sweats, unexplained fever, weight loss and bone pain.

The first test is usually a full blood count — cheap, fast and widely available. From there, diagnosis depends on the disease: a lymph node biopsy for lymphoma (the whole node where possible, not a needle sample), a bone marrow biopsy for leukemia and myeloma, and blood and urine protein tests for myeloma.

In every blood cancer, ask for the exact subtype and the genetic findings. Flow cytometry, cytogenetics and molecular testing are not academic extras here — they decide whether you receive a daily tablet, intensive chemotherapy, or a transplant.

Staging explained simply

Blood cancers do not use the TNM staging you may have read about. They begin in blood, marrow and lymph tissue — systems that already run throughout the body — so "has it spread?" is rarely the useful question. Each disease uses its own framework:

• Lymphoma — Ann Arbor staging (I–IV), based on which side of the diaphragm is involved, with A or B for the absence or presence of fevers, night sweats and weight loss.
• Leukemia — no standard staging system at all. Described as untreated, in remission or recurrent, with risk classification (ELN, Rai, Binet, or CML phase) doing the real work.
• Myeloma — the Revised International Staging System (R-ISS), built from blood tests and genetics rather than anatomy.

This is why searching "stage 4 leukemia" returns nothing coherent. It is not that information is being kept from you; the concept does not apply.

Grading and biology

Instead of a 1–3 grade, blood cancers are sorted by pace and by genetics.

Pace: acute or aggressive disease grows fast and needs treatment promptly — and is often the curable kind. Chronic or indolent disease progresses over years, may be monitored rather than treated, and is very treatable but frequently not curable. Being told your disease is aggressive is frightening, and is often better news than the alternative.

Genetics carry the weight: FLT3 and NPM1 in AML, the Philadelphia chromosome in CML, TP53 in CLL, del(17p) and t(4;14) in myeloma, MYC and BCL2 in lymphoma. Measurable residual disease (MRD) — finding one cancer cell among a million normal ones — is now among the strongest predictors of outcome across this whole group.

How they’re treated

Systemic therapy leads, because these are diseases of a system rather than a lump: chemotherapy, targeted tablets, antibodies, immunotherapy, and stem cell transplant.

Watchful waiting is a real treatment plan for early CLL, indolent lymphoma, MGUS and smouldering myeloma. Treating sooner has not been shown to help, and it spends side effects you may not need for years. It should always come with a monitoring schedule.

Radiation's role varies enormously across this group, and we would rather be precise than promotional:

• Lymphoma — a genuine leading role. Lymphoma is among the most radiosensitive cancers; involved-site radiation treats early-stage disease and very low doses control indolent disease or relieve symptoms.
• Myeloma — valuable and specific: bone pain, plasmacytoma, impending fracture, spinal cord compression.
• Leukemia — a narrow supporting role: total body irradiation before transplant, chloroma, brain or testicular disease in ALL, splenic radiation.

Where CureRays fits: we are radiation specialists working alongside your haematologist, who leads. In lymphoma and myeloma bone disease we contribute a lot; in leukemia, less. We will tell you which.

What the guidelines say

The common shape: get an adequate biopsy and an exact subtype before treating; test the genetics; use risk classification rather than anatomical stage to decide intensity; observe asymptomatic indolent disease; measure response including MRD; and manage supportive care — infection prevention, vaccination, bone protection, fertility — as part of treatment rather than an afterthought.

Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The above is a plain-language overview of the general approach, not the guideline itself. NCCN publishes free NCCN Guidelines for Patients® for each of these diseases.

Outcomes and odds of cure

A single "blood cancer" survival figure would be meaningless, because this label covers childhood ALL (cure rates above 90% in many series) and AML in an older adult in the same breath. Go to the page for your disease:

• Non-Hodgkin lymphoma — 5-year relative survival about 74% overall, and about 64% even at stage IV (NCI SEER, SEER 17, 2014–2020).
• Myeloma — about 64%, up from roughly 30% in the mid-1990s (NCI SEER, SEER 21 excluding IL, 2015–2021).
• Leukemia — reported by subtype; see the AML, ALL, CLL and CML pages linked from our leukemia page.

The direction of travel across all three is unambiguously good: lymphoma death rates falling about 2.1% a year, myeloma about 2.6% a year, and CML converted from a fatal disease into one managed with a daily tablet within a single generation.

These are population statistics from the National Cancer Institute's SEER program. They describe large groups of people, not any one person, and lag current treatment by several years. They cannot predict what will happen to you.

Side effects and how we watch for them

The one thing to remember from this whole page: during treatment, a fever is an emergency. When your white count is low, infection can become dangerous within hours, and antibiotics are needed within the hour — not tomorrow morning. Do not take paracetamol to see whether it settles. Know your unit's 24-hour number.

Also common: anaemia and low platelets needing transfusion, mouth sores, nausea, hair loss with some regimens, and fatigue that outlasts treatment by months. Steroids disrupt sleep and mood. Some targeted drugs cause neuropathy, clot risk or blood pressure changes — all usually managed by dose adjustment rather than stopping.

Radiation effects depend entirely on the site treated. Where the chest or neck is involved in a young person, technique is chosen specifically to limit long-term heart, thyroid, breast and second-cancer risk.

How it is assessed: graded at every visit on a standard scale, with continuous blood count monitoring and disease-specific markers tracked over time.

Follow-up, remission and survivorship

Remission means no detectable disease by the measure that applies — PET/CT in lymphoma, marrow blasts under 5% in leukemia, the paraprotein level in myeloma. MRD-negative remission is deeper and increasingly guides whether more treatment is needed.

Follow-up is mostly clinical review and blood tests, frequent at first and stretching out over years. Routine surveillance scanning is used less than it once was in lymphoma, because most relapses are found by symptoms rather than scans.

Survivorship in blood cancer is a long project, because many survivors are young and treatment reaches the whole body: heart function after anthracyclines, thyroid after neck radiation, fertility (raise it before treatment starts), bone density, cataracts and second cancers after transplant or total body irradiation, and revaccination — childhood immunity is lost after transplant and the whole schedule must be repeated. Ask for a written survivorship plan naming who watches what, how often, and whom to call.

Questions people actually ask

Informational only, not medical advice — confirm with your care team.

Talk with a radiation specialist

If radiation has been mentioned as part of your blood cancer treatment, we will review your case and explain honestly what it can and cannot do.

Contact CureRays